August 2026 Research Update

This month added more detail about how trofinetide is being used in everyday Rett syndrome care, and what people look for when judging whether a treatment is helping. One large US dataset described differences between adults who did versus did not receive trofinetide, without measuring symptom change. A separate clinician consensus and a caregiver survey both emphasized that day-to-day function and tolerability are central to how families and clinicians think about meaningful benefit. [1] [2] [3]

In US claims and specialty pharmacy data, 290 of 1,820 adults with Rett syndrome had records consistent with receiving trofinetide, and the treated group was slightly younger on average. The treated group also had higher recorded rates of some overlapping diagnoses and Rett-related features, while the overall comorbidity burden looked similar between treated and untreated groups in this dataset. This helps set expectations about who is currently getting trofinetide in practice, but it does not answer whether symptoms improved. [1]

A US expert panel of trofinetide-experienced clinicians reached agreement across many practical statements about starting and following trofinetide, especially around setting a baseline and tracking changes with caregiver notes. They also agreed that stomach and bowel side effects like diarrhea and vomiting are common, and described management approaches that often involve adjustments rather than stopping right away. This reflects real-world experience rather than a head-to-head test of different approaches. [2]

Caregivers across 4 countries described that the most impactful Rett-related losses are often already present by age 6, including loss of speech, loss of purposeful hand use, and gait problems. When asked what would be meaningful if gene therapies were available, caregivers most often pointed to improvements in communication, motor function, and independence in daily activities. This adds clarity about what outcomes families most want research studies to measure. [3]

For patients and caregivers, these studies mostly add context rather than proving that any approach works better than another. The adult claims analysis may matter now because it shows who is currently receiving trofinetide in the US and highlights that medical records can include overlapping diagnoses like cerebral palsy or autism, which may reflect how Rett syndrome is coded in routine care. The clinician consensus may matter now as a description of commonly used strategies for monitoring and managing side effects, but it is not the same as trial evidence. The caregiver survey may matter later by pushing research (especially gene therapy research) to measure changes in communication, movement, and independence that families would notice in everyday life. [1] [2] [3]

What remains uncertain this month is how much trofinetide changes specific symptoms in adults outside of clinical trials, because the real-world dataset focused on characteristics of treated versus untreated groups rather than outcomes. It is also unclear how broadly the consensus statements apply outside specialized US Rett centers, and whether different families would rank outcomes differently than this caregiver group. Even with those gaps, the combined message is clearer: tracking real-life function and managing tolerability are central to treatment discussions, and families want studies to focus on abilities like communication and motor skills. [1] [2] [3]

This month strengthened the idea that how we measure Rett-related symptoms matters, and that different tools can capture different parts of the condition. One large questionnaire study highlighted that sleep-related breathing concerns stand out in Rett syndrome compared with other neurodevelopmental conditions and neurotypical siblings. A separate EEG study reported an elevated brain-wave pattern in many children with Rett syndrome and related genetic conditions, suggesting a possible way to group patients for research. [4] [5]

Across Angelman, Prader-Willi, and Rett syndromes, caregivers commonly reported night waking and snoring, but the Rett group had the highest scores for sleep-disordered breathing on questionnaires. Over about 12 months in a follow-up subset, scores in Angelman and Rett changed in varied ways, but breathing-related scores consistently increased in both, while neurotypical siblings' scores fell on many sleep measures (though not on breathing). This supports the idea that sleep and breathing issues can be persistent and measurable over time, at least using caregiver reports. [4]

In a cross-sectional EEG study spanning autism and several genetic conditions, the researchers reported elevated rates of transient beta events (a brief EEG pattern) in a majority of children with Rett syndrome, Phelan-McDermid syndrome, and SYNGAP1-related disorder. They also reported that only some children with idiopathic autism showed the same elevation. This points to a potential research marker that could help sort neurodevelopmental conditions into more biologically similar groups, but the summary does not include how well it matches day-to-day symptoms. [5]

For families, these studies are mainly about understanding and measurement rather than new treatments. The sleep study may matter now because it reinforces that sleep-related breathing concerns are common in Rett syndrome and can be tracked over time using caregiver questionnaires, even though questionnaires cannot replace objective sleep testing. The EEG finding may matter later because it offers a possible way to group patients in research studies, but it is not yet described here as a test used for diagnosis or for guiding care. [4] [5]

What remains uncertain is how strongly these questionnaire scores and EEG patterns connect to specific daily challenges for an individual person, and whether changing them would translate into meaningful improvement. The month still adds something practical: it highlights concrete, trackable areas (sleep and breathing symptoms, and EEG markers) that researchers are trying to measure consistently in Rett syndrome and related conditions. [4] [5]

This month connected MECP2 changes in the lab to the wide range of ways MECP2-related conditions can look in real life. One preclinical study explained why some specific frameshift changes near the end of MECP2 can act very differently, and it showed that mice built to carry a corrective change did not develop Rett-like symptoms; the gene-editing tool that could make this change has so far been tested only in cultured cells. At the same time, clinical reports reminded readers that MECP2 variants can present without classic Rett features, and that rare additional medical problems can occur in single individuals. [6] [7] [8]

In mouse and cell work, researchers reported that MECP2 frameshift mutations in the protein tail can be either harmful or seemingly benign depending on which reading frame they shift into, because the ending sequence changes. In their models, one class of endings reduced MeCP2 levels and produced Rett-like features, while another class maintained typical MeCP2 levels and did not. They also showed that introducing a specific genetic change restored MeCP2 levels and rescued Rett-like features in mice, and separately demonstrated that a base editor could make the same change in cultured cells. This frames a possible future research direction rather than a ready-to-use therapy. [6]

A case series of 5 unrelated people with pathogenic MECP2 variants described presentations that did not fit classic Rett syndrome, including mild neurodevelopmental issues with epilepsy and no Rett features in two girls with Xq28 deletions involving MECP2. It also included a boy with intellectual disability, autism, and focal epilepsy, plus two older individuals with movement and coordination problems and preserved cognition in one case. Together, these reports broaden the picture of what MECP2-related conditions can look like across sexes and ages. [7]

One case report described a 20-year-old woman with Rett syndrome who developed pemphigus foliaceus, an autoimmune blistering skin disease, with a difficult course and partial improvement after rituximab. The report included genetic and immune-risk markers, but it could not establish whether Rett syndrome contributed to the skin condition. This mainly serves as a reminder that individuals with Rett syndrome can still develop unrelated rare illnesses that require specialized evaluation. [8]

Another translational study looked at the HRH3 receptor (a brain signaling protein) in human Rett brain tissue and Rett-model mice, and then tested drugs that target this receptor in mouse models. The researchers reported reduced HRH3 levels in most Rett samples, but the tested HRH3-targeting drugs produced little to no behavioral improvement in their models. This is an example of a biological lead that did not translate into clear benefit in early testing. [9]

For patients and caregivers, most of this section is early-stage or descriptive research. The frameshift and base-editing study may matter in the future because it offers a clearer explanation for why some MECP2 changes cause disease while others may not, and it points to a potential path to correcting a subset of mutations, so far tested only in engineered mice and cultured cells. The clinical case series may matter now by reinforcing that MECP2-related conditions can be diagnosed even when classic Rett features are missing, although this report does not test a screening strategy. The pemphigus case report and the HRH3 drug study mainly add awareness of rare situations and early research directions rather than changing day-to-day care. [6] [7] [8] [9]

What remains uncertain is how soon gene-editing approaches could be tested safely in people, and whether the mouse results will translate to meaningful human outcomes. It is also unclear how often the atypical MECP2 presentations described in the small case series occur in the wider population. Even so, this month made two points clearer: MECP2-related disorders cover a broader range than classic Rett syndrome, and not every biological difference found in the lab will lead to a helpful drug signal right away. [6] [7] [9]